Literature DB >> 17287945

Imatinib-induced Stevens-Johnson syndrome: recurrence after re-challenge with a lower dose.

Manoranjan Mahapatra, Pravas Mishra, Rajat Kumar.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17287945     DOI： 10.1007/s00277-007-0265-y

Source DB:  PubMed          Journal:  Ann Hematol        ISSN： 0939-5555            Impact factor:   3.673


× No keyword cloud information.
  6 in total

1.  Serious skin reaction associated with imatinib in a patient with chronic myeloid leukemia.

Authors:  Murat Albayrak; Harika Celebi; Aynur Albayrak; Esra Saribacak Can; Vedat Aslan; Birgul Onec; Ipek Coban
Journal:  Eurasian J Med       Date:  2011-12

2.  Life-threatening dermatologic adverse events in oncology.

Authors:  Alyx C Rosen; Yevgeniy Balagula; Dennis W Raisch; Vishvas Garg; Beatrice Nardone; Nicole Larsen; Jennifer Sorrell; Dennis P West; Milan J Anadkat; Mario E Lacouture
Journal:  Anticancer Drugs       Date:  2014-02       Impact factor: 2.248

3.  Skin and oral lesions associated to imatinib mesylate therapy.

Authors:  Fernanda Gonçalves Basso; Camila Cominato Boer; Maria Elvira Pizzigatti Corrêa; Marcia Torrezan; Maria Letícia Cintra; Marina H C Gallottini de Magalhães; Paulo da Silva Santos; Cármino Antônio de Souza
Journal:  Support Care Cancer       Date:  2008-11-27       Impact factor: 3.603

Review 4.  Potentially life‑threatening severe cutaneous adverse reactions associated with tyrosine kinase inhibitors (Review).

Authors:  Emily L Coleman; Brianna Olamiju; Jonathan S Leventhal
Journal:  Oncol Rep       Date:  2020-12-24       Impact factor: 3.906

Review 5.  Anticancer Drugs Induced Severe Adverse Cutaneous Drug Reactions: An Updated Review on the Risks Associated with Anticancer Targeted Therapy or Immunotherapies.

Authors:  Chau Yee Ng; Chun-Bing Chen; Ming-Ying Wu; Jennifer Wu; Chih-Hsun Yang; Rosaline Chung-Yee Hui; Ya-Ching Chang; Chun-Wei Lu
Journal:  J Immunol Res       Date:  2018-01-17       Impact factor: 4.818

Review 6.  Severe cutaneous adverse reactions induced by targeted anticancer therapies and immunotherapies.

Authors:  Chun-Bing Chen; Ming-Ying Wu; Chau Yee Ng; Chun-Wei Lu; Jennifer Wu; Pei-Han Kao; Chan-Keng Yang; Meng-Ting Peng; Chen-Yang Huang; Wen-Cheng Chang; Rosaline Chung-Yee Hui; Chih-Hsun Yang; Shun-Fa Yang; Wen-Hung Chung; Shih-Chi Su
Journal:  Cancer Manag Res       Date:  2018-05-17       Impact factor: 3.989
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.